Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
5 minute read

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

By Shanthi Rexaline
Today, 10:41 AM
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and Drug Administration approved by May 2021.

ACAD

Read More
2 minute read

Partner Of Myovant Sciences’ Sumitovant, Urovant Sciences, Highlights Presentation Of Interim Data From Phase 2a Study Of Investigational Novel Gene Therapy, URO-902, At American Urological Association Meeting

By Benzinga Newsdesk
Today, 10:41 AM
Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the common symptoms of

MYOV

Read More
1 minute read

Earnings Preview: Myovant Sciences

By Benzinga Insights
Today, 10:41 AM
Myovant Sciences (NYSE:MYOV) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Myovant Sciences will report an earnings per share (EPS) of $-0.57.

MYOV